About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
CLL Toxicities Associated with BCR Kinase and BCL-2 Inhibitors
By
Richard Furman
0 views
September 8, 2018
Comments
0
Login to view comments.
Click here to Login
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Featured Video
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
06:53
UC Irvine Health
Fixed-Duration Treatment in CLL: Current Considerations
Feat.
E. Brem
25:47
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in Indolent B-Cell Lymphomas
Feat.
J. Soumerai
24:33
Indy Hematology Review
Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…
Feat.
J. Woyach
03:06
City of Hope
CLL Treatment Sequencing: The Importance of First Choice
Feat.
S. Rosen
08:17
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing i…
06:56
Insights from 2023 ASH Annual Meeting
Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…
Feat.
M. Shadman
06:59
Constantine Tam
R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…
15:21
5th SOHO Italy Annual Conference
How I Treat CLL at the MD Anderson Cancer Center
Feat.
A. Ferrajoli
08:42
City of Hope
Venetoclax vs. BTKis in CLL Treatment
Feat.
A. Danilov
08:45
Insights from 2023 ASH Annual Meeting
The Best of CLL: Highlights & Key Takeaways
Feat.
V. Yazbeck
19:14
2024 ASCO® Annual Meeting Insights Hub
Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…
Feat.
K. Rogers,
J. Woyach
10:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…
Feat.
J. Woyach
06:34
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…
Feat.
A. Kittai
22:47
Indy Hematology Review
CLL: Evaluating and Therapeutic Approaches for the Management of the…
Feat.
J. Woyach
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
10:19
Alvaro Alencar
Pirtobrutinib in R/R CLL
